DNX-2401 wins $2 million FDA grant for cancer immunotherapy
DNX-2401 has won a $2 million grant from the Food and Drug Administration to support clinical trials of a virus-driven immunotherapy for cancer. The company is evaluating its DNX-2401 product,…